In preclinical studies, exposure of NAPRT-positive ovarian and pancreatic cancer cells to 2-HNA sensitized them to NAMPT inhibitors and recapitulated the effect of NAPRT silencing. This evidence concerns the gene NAPRT and pancreatic neoplasm.